Business Wire

HPCAIAC

8.4.2020 14:32:09 CEST | Business Wire | Press release

Share
HPC-AI Advisory Council and National Supercomputing Centre Singapore Expand 3rd APAC HPC-AI Competition to Address COVID-19

The HPC-AI Advisory Council (HPCAIAC) and the National Supercomputing Centre (NSCC) Singapore announced today that they have joined the global fight against COVID-19 by expanding the 2020 APAC HPC-AI competition to address education and applied learning towards accelerating bioscience research and discovery.

As part of the updated competition, student teams are now tasked to research, find and choose an HPC or AI application that can potentially be used as part of the global fight against COVID-19. Teams must demonstrate testing and benchmarking of the application, as well as explain how this application can best be accelerated. In addition, teams will also be required to focus on tuning and accelerating NAMD, a molecular dynamics code designed for high-performance simulation of large biomolecular systems. The NAMD application is being used at various supercomputing sites to run massive simulations of COVID-19 to aid researchers design new drugs and vaccines to combat the virus.

The APAC HPC-AI competition promotes the latest HPC and AI technologies to the universities and research centers and trains the students with the latest HPC and AI technologies to help bridge the gap between universities/research institutes and industries. The competition also trains the undergraduate and graduate students to practice on the newest HPC and AI platforms, and provides the key ingredients and industry tools to optimize the production applications. Open for registration until May 17, the 3rd Annual 2020 APAC HPC-AI competition expects to host multiple teams from across the APAC region.

“While not ignoring commercial and scientific applications, it has become importantly clear that we must put further emphasis on tuning and optimizing applications in the medical and bioscience field. By expanding the competition’s charter to address applications specifically used for groundbreaking COVID-19 simulations, the HPC-AI Advisory Council and NSCC are taking the action to educate and train the next generation of HPC scientists and programmers that may aid the world in viral outbreaks or pandemics in the future,” said Gilad Shainer, Chairman of the HPC-AI Advisory Council.

"Computer models of viruses and viral protein structures, especially for high resolution analysis, is very computationally intensive. Molecular docking experiments in silico, to screen for potentially effective drugs that block viral functions, and molecular-modeling applications, such as GROMACS and NAMD, must be optimized and benchmarked for simulations to run as efficiently as possible. By training our young aspiring programmers using real-world scenarios such as COVID-19, we can better prepare them to provide solutions to future global issues from pandemics to climate change. More than that, we hope that this will give our youth a better appreciation for the significant role that HPC and AI can play, and how they can use the skills learned in this competition to contribute more meaningfully to society," said Professor Tan Tin Wee, Chief Executive, National Supercomputing Centre (NSCC) Singapore.

Co-organized by the HPC-AI Advisory Council and NSCC, the competition is sponsored by Mellanox, NVIDIA, AMD and WekaIO with additional support from the Singapore Advanced Research and Education Network (SingAREN).

For more information on the 3rd APAC HPC-AI competition and to register teams, please visit the HPC-AI Advisory Council website at http://hpcadvisorycouncil.com/events/2020/APAC-AI-HPC/

About HPC-AI Advisory Council

Founded in 2008, The HPC-AI Advisory Council (HPCAIAC) is a for community benefit organization with over 400 members committed to bridge the gap between high-performance computing and artificial intelligence use and its potential, bringing the beneficial capabilities of HPC and AI to new users for better research, education, innovation and product manufacturing, and brings users the expertise needed to operate HPC and AI systems, provide application designers with the tools needed to enable parallel computing, and to strengthen the qualification and integration of HPC and AI system products. For more information, please visit: www.hpcadvisorycouncil.com .

About National Supercomputing Centre Singapore

The National Supercomputing Centre (NSCC) Singapore was established in 2015 and manages Singapore’s first national petascale facility with available high performance computing (HPC) resources. As a National Research Infrastructure we support the HPC research needs of the public and private sectors, including research institutes, institutes of higher learning, government agencies and companies. With the support of its stakeholders, including Agency for Science Technology and Research (A*STAR), Nanyang Technological University (NTU), National University of Singapore (NUS), Singapore University of Technology and Design (SUTD), National Environment Agency (NEA) and Technology Centre for Offshore and Marine, Singapore (TCOMS), and funded by the National Research Foundation (NRF), NSCC catalyses national research and development initiatives, attracts industrial research collaborations and enhances Singapore’s research capabilities. For more information, please visit https://www.nscc.sg/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release

A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye